Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.81 USD | -0.75% | -1.85% | -33.49% |
05-31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
05-24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.49% | 4.83B | |
-0.28% | 90.59B | |
-0.92% | 38.99B | |
-9.57% | 34.09B | |
-17.98% | 15.02B | |
-6.74% | 13.17B | |
-9.76% | 11.88B | |
-47.31% | 10.65B | |
+7.27% | 9.25B | |
+137.06% | 9.02B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals Insider Sold Shares Worth $1,467,240, According to a Recent SEC Filing